Gossamer Bio Inc. (NASDAQ: GOSS)
$1.24
+0.0600 ( +5.08% ) 4.3M
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Market Data
Open
$1.24
Previous close
$1.18
Volume
4.3M
Market cap
$282.77M
Day range
$1.18 - $1.33
52 week range
$0.45 - $1.88
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 16 | Mar 12, 2024 |
4 | Insider transactions | 1 | Mar 12, 2024 |
3 | Insider transactions | 2 | Mar 12, 2024 |
3 | Insider transactions | 2 | Mar 12, 2024 |
4 | Insider transactions | 1 | Mar 12, 2024 |
10-k | Annual reports | 88 | Mar 05, 2024 |
8-k | 8K-related | 16 | Mar 05, 2024 |
8-k | 8K-related | 14 | Mar 04, 2024 |
4 | Insider transactions | 1 | Jan 04, 2024 |
4 | Insider transactions | 1 | Jan 04, 2024 |